Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)

COVID-19 is an emerging, rapidly evolving situation.

MEMORANDUMS

PLEASE NOTE: This is a reminder that infections occurring in subjects on clinical trials are considered adverse events, please see this additional guidance for reporting COVID-19 related adverse event.

Phase 0-I-II Prevention Clinical Trials Program Being Replaced with Grant Program

The National Cancer Institute is accepting applications for the Cancer Prevention Clinical Trials Network (CP-CTNet), a grant-funded network that will replace the contract-funded Phase 0-I-II Prevention Clinical Trials Program (Consortia). CP-CTNet will perform early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. For more information, List of Consortia Trials

  • List of Published Results from Completed Consortia Studies
  • Consortia Clinical Trial Management Information